CALCITRIOL INJECTION USP SOLUTION

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

CALCITRIOL

Dostopno od:

STERIMAX INC

Koda artikla:

A11CC04

INN (mednarodno ime):

CALCITRIOL

Odmerek:

1MCG

Farmacevtska oblika:

SOLUTION

Sestava:

CALCITRIOL 1MCG

Pot uporabe:

INTRAVENOUS

Enote v paketu:

15G/50G

Tip zastaranja:

Prescription

Terapevtsko območje:

VITAMIN D

Povzetek izdelek:

Active ingredient group (AIG) number: 0113628002; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2013-01-29

Lastnosti izdelka

_ _
_Calcitriol Injection USP Product Monograph _
_Page 1 of 24 _
_ _
PRODUCT MONOGRAPH
PR
CALCITRIOL INJECTION USP
1 mcg/mL
Vitamin D
3
Metabolite
SteriMax Inc.
2770 Portland Drive
Oakville, ON
Canada
L6H 6R4
Date of Revision:
February 24, 2023
Control No : 241232
_ _
_Calcitriol Injection USP Product Monograph _
_Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
..................................................